Skip to main content
Figure 7 | BMC Cancer

Figure 7

From: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

Figure 7

Effects of Panagen on patient cytokine profiles. Comparison of spontaneous and mitogen-stimulated cytokine secretion in Control (n = 4) and Panagen-treated (n = 12) patients under FAC chemotherapy regimen and in Control (n = 6) and Panagen-treated (n = 19) patients under AC chemotherapy regimen. T0 – before the therapy, Т1 – day 21 after the first chemotherapy, Т2 – day 21 after the third chemotherapy. Results were analyzed by One Way Repeated Measures and Two Way ANOVA with post hoc Holm-Sidak and Tukey tests in order to evaluate significance of interval-dependent changes, as well as difference between groups. Absolute units of measure (pg/ml) were converted to natural logarithms in order to normalize data prior to analysis. Data presented as Mean ± SEM; a,b – statistically significant difference (p < 0.05) vs T0 or T1 interval respectively; c – statistically significant difference (p < 0.05) between Panagen and Control groups.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us